1 We estimated 1-year mortality in each condition, developing s
2 In a do nothing scenario,
we estimated 146 996 excess deaths with an RR of 1.5, 293 991
3 Using the self-controlled case-series method,
we estimated age-adjusted incidence rate ratios within 1-7, 8
4 search HIV Clinical Cohort receiving care during 1996-2016,
we estimated annual hospitalization rates, time to inpatient
5 We estimated ARI visits and antibiotic prescriptions averted
6 We estimated associations between fruit and vegetable intake
7 We estimated associations of repeated pre- and postnatal seru
8 We estimated costs by applying the eligibility criteria for t
9 Using the count,
we estimated Cox proportional hazard models to examine associ
10 We estimated differences in patient-reported urinary, bowel,
11 We estimated foodshed size, colloquially known as "food miles
12 Here,
we estimated harvest and background (other cause) mortality o
13 We estimated healthcare provider direct medical economic cost
14 From the simulated infections,
we estimated hospitalizations, deaths, and healthcare needs e
15 To assess the risk of metabolic syndrome
we estimated HRs and 95% CIs using Cox proportional hazards m
16 We estimated human immunodeficiency virus incidence and incid
17 We estimated incidence rate ratios (RRs) and 95% confidence i
18 We estimated incidence, hospital admission rates, and in-hosp
19 We estimated occupational noise exposure for each case and co
20 We estimated OPO-level donation rates using CDC data, and use
21 For the same period,
we estimated reductions in pollutant emissions of more than a
22 We estimated sex- and smoking-specific incidence trends of pr
23 developed microsimulation model of global cancer survival,
we estimated stage-specific cervical cancer 5-year net surviv
24 ends in individual countries.Measurements and Main Results:
We estimated TB cases, deaths, and costs and the total econom
25 We estimated that 1.7 billion (UI 1.0-2.4) people, comprising
26 We estimated that 168,065.18 (95% CI: 114,144.91-221,985.45)
27 We estimated that a 10-fold increase in the abundance in Stre
28 We estimated that a single follow-up examination at the end o
29 Based on these values
we estimated that approximately 16%-46% of the decreased CVD-
30 We estimated the 10-year predicted risk of CVD using the Amer
31 m two publicly available human genomic diversity resources,
we estimated the age of more than 45 million single-nucleotid
32 We estimated the association between baseline demographic cha
33 We estimated the association between chronic HCV (RNA+) and t
34 Doing so,
we estimated the best parameter sets of the ecophysiological
35 We estimated the community incidence, hospitalization rate, a
36 For participants without SILs at baseline,
we estimated the cumulative incidence and risk factors for SI
37 Where appropriate,
we estimated the effect of corticosteroids by random-effects
38 t least 3 PET/CT scans after administration of (124)I-MIBG,
we estimated the effective dose of (124)I-MIBG.
39 Here
we estimated the effects of 1,002 proteins on 225 phenotypes
40 Using physical models,
we estimated the frequency of exceeding the thermal optimum (
41 transmission model calibrated to data in the United States,
we estimated the impact of POCT on chlamydia prevalence, inci
42 We estimated the number of in-hospital deaths due to RSV-ARI
43 We estimated the prevalence of total HBV core antibody (anti-
44 nd survival information with cohort-specific survival data,
we estimated the relative risks of mortality from ages 95 to
45 Pregnancy outcomes were self-reported, and
we estimated the RR (95% CI) of pre-eclampsia and GHTN with l
46 Here,
we estimated the temperature response of g(m) , g(bs) and lea
47 We estimated the VA decline rate over 8 years using a linear
48 Among candidates,
we estimated time to listing, waitlist mortality, and transpl
49 We estimated transition probabilities from randomized trials
50 We estimated VI and blindness prevalence rates and confidence